Eli Lilly said its top-selling diabetes drug, Trulicity, significantly reduced the risk of heart attack, stroke and heart-related death in a broad range of people with type 2 diabetes, according to results of a large late-stage clinical trial.
According to the drugmaker, Trulicity is the first type 2 diabetes medicine to show this sort of statistically significant heart risk reduction in a clinical trial in which a majority of patients did not already have heart disease.
Only 31 percent of those in the 9,901-patient REWIND study had heart disease, said the drugmaker. The trial compared 1.5 milligrams of Trulicity once a week to placebo, with the primary goal a reduction in a composite of major adverse events that included non-fatal heart attack, non-fatal stroke and heart-related death.
The company plans to submit the data to regulatory authorities next year and present the findings at the American Diabetes Association Scientific Sessions in June 2019 in San Francisco.
Read the press release